NASDAQ:CFRX ContraFect (CFRX) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free CFRX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.05▼$0.0650-Day Range$0.05▼$0.0752-Week Range$0.04▼$13.02Volume910,200 shsAverage Volume1.39 million shsMarket Capitalization$535,000.00P/E RatioN/ADividend YieldN/APrice Target$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesOwnershipShort InterestSocial Media Get ContraFect alerts: Email Address ContraFect MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside5,900.0% Upside$3.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.44) to ($1.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.78 out of 5 stars 3.5 Analyst's Opinion Consensus RatingContraFect has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, ContraFect has a forecasted upside of 5,900.0% from its current price of $0.05.Amount of Analyst CoverageContraFect has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for CFRX. Previous Next 0.0 Dividend Strength Dividend YieldContraFect does not currently pay a dividend.Dividend GrowthContraFect does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CFRX. Previous Next 0.6 News and Social Media Coverage Search Interest1 people have searched for CFRX on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ContraFect insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.62% of the stock of ContraFect is held by insiders.Percentage Held by InstitutionsOnly 7.85% of the stock of ContraFect is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ContraFect are expected to grow in the coming year, from ($3.44) to ($1.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ContraFect is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ContraFect is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About ContraFect Stock (NASDAQ:CFRX)ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.Read More Ad DTIWarning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…Watch the presentation here CFRX Stock News HeadlinesJanuary 9, 2024 | morningstar.comContraFect Corp CFRXQNovember 19, 2023 | morningstar.comContraFect Corp CFRXMarch 29, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. November 14, 2023 | washingtonpost.comContraFect: Q3 Earnings SnapshotOctober 23, 2023 | benzinga.comWhy Troika Media Group Shares Are Trading Lower By Over 20%; Here Are 20 Stocks Moving PremarketOctober 16, 2023 | msn.comWhy Is ContraFect (CFRX) Stock Up 23% Today?October 16, 2023 | finance.yahoo.comContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical StudyOctober 10, 2023 | benzinga.comWhy Immunic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving PremarketMarch 29, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. September 21, 2023 | finance.yahoo.comCFRX: IND Application for CF-370 Submitted to FDA…September 19, 2023 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: ContraFect (CFRX), Boston Scientific (BSX)September 19, 2023 | finance.yahoo.comContraFect to Present at the ASM/ESCMID Joint Conference on Drug DevelopmentSeptember 18, 2023 | finance.yahoo.comContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370August 28, 2023 | finance.yahoo.comContraFect to Present at the World Anti-Microbial Resistance Congress 2023August 17, 2023 | finance.yahoo.comCFRX: CF-370 IND to be Filed in 3Q23…August 15, 2023 | markets.businessinsider.comContraFect (CFRX) Receives a Buy from Maxim GroupAugust 14, 2023 | sfgate.comContraFect: Q2 Earnings SnapshotAugust 14, 2023 | finance.yahoo.comContraFect Reports Second Quarter 2023 Financial Results and Provides Business UpdateJuly 25, 2023 | money.usnews.comContraFect CorpJuly 6, 2023 | msn.comContraFect (CFRX) Price Target Decreased by 97.37% to 5.10June 27, 2023 | msn.comContraFect enters a warrant exercise transaction for $9.6MJune 27, 2023 | finance.yahoo.comContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 MillionJune 22, 2023 | marketwatch.com8-K: CONTRAFECT CorpJune 22, 2023 | finance.yahoo.comCFRX: CF-370 Effective in Rabbit Lung Infection Model Caused by Klebsiella Pneumoniae…June 20, 2023 | finance.yahoo.comContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company’s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative PathogensJune 9, 2023 | msn.comContraFect Gains with Key Data Presentation Set for Next WeekJune 8, 2023 | finance.yahoo.comContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023See More Headlines Receive CFRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ContraFect and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CFRX CUSIPN/A CIK1478069 Webwww.contrafect.com Phone(914) 207-2300FaxN/AEmployees23Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside+5,900.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($19.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-65,150,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-138.70% Debt Debt-to-Equity RatioN/A Current Ratio0.53 Quick Ratio0.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($19.92) per share Price / Book0.00Miscellaneous Outstanding Shares10,700,000Free Float10,639,000Market Cap$535,000.00 OptionableNot Optionable Beta0.29 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Roger James Pomerantz FACP (Age 66)M.D., Chairman, CEO & President Comp: $970.72kMr. Michael Messinger CPA (Age 48)Chief Financial Officer Comp: $543.14kMs. Natalie Bogdanos J.D. (Age 54)General Counsel, Corporate Secretary & Data Protection Officer Comp: $531.2kMr. Matthew Salamone P.H.R.SPHR, Vice President of Human ResourcesDr. Gary Woodnutt (Age 66)Senior Vice President of Translational Sciences & Preclinical Development Dr. William Garrett Nichols M.D. (Age 54)M.S., Interim Chief Medical Officer More ExecutivesKey CompetitorsGalmed PharmaceuticalsNASDAQ:GLMDRevelation BiosciencesNASDAQ:REVBGRI BioNASDAQ:GRIObsEvaNASDAQ:OBSVAvalo TherapeuticsNASDAQ:AVTXView All Competitors CFRX Stock Analysis - Frequently Asked Questions Should I buy or sell ContraFect stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CFRX shares. View CFRX analyst ratings or view top-rated stocks. What is ContraFect's stock price target for 2024? 1 analysts have issued 12 month price objectives for ContraFect's shares. Their CFRX share price targets range from $3.00 to $3.00. On average, they predict the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 5,900.0% from the stock's current price. View analysts price targets for CFRX or view top-rated stocks among Wall Street analysts. How were ContraFect's earnings last quarter? ContraFect Co. (NASDAQ:CFRX) announced its quarterly earnings data on Monday, November, 15th. The biotechnology company reported ($10.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($22.64) by $12.24. When did ContraFect's stock split? Shares of ContraFect reverse split before market open on Tuesday, February 14th 2023. The 1-80 reverse split was announced on Tuesday, February 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What other stocks do shareholders of ContraFect own? Based on aggregate information from My MarketBeat watchlists, some companies that other ContraFect investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Verastem (VSTM), Vaxart (VXRT), Matinas BioPharma (MTNB), VBI Vaccines (VBIV), Novavax (NVAX), Cidara Therapeutics (CDTX), Gilead Sciences (GILD) and Dynavax Technologies (DVAX). Who are ContraFect's major shareholders? ContraFect's stock is owned by many different retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. This page (NASDAQ:CFRX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryOnly a fool would buy Nvidia today… Porter & CompanyAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ContraFect Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.